Francesca Toffalorio

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

Lorlatinib in patients with ALK-positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study.

Lorlatinib in patients with ALK-positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study.

Journal: Future oncology (London, England)

Published: April 08, 2026

Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.

Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: April 07, 2026

First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study.

First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: January 17, 2025

Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer.

Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer.

Journal: Future oncology (London, England)

Published: October 03, 2024

Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report.

Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: August 29, 2024

Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.

Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 31, 2024

Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.

Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.

Journal: Future oncology (London, England)

Published: June 12, 2023

Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC.

Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: August 05, 2022

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.

Journal: The Lancet. Respiratory medicine

Published: August 02, 2022

Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.

Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 24, 2022

Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease.

Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: August 04, 2021

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 07, 2020

Showing 1-12 of 34

Last Updated: 09/26/2026